VX-864 – Patient Worthy

source: pixabay.com

Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation

Post author:Jessica Lynn
Post published:July 27, 2021
Post category:Alpha-1 Antitrypsin Deficiency Alpha-1 antitrypsin deficiency

Medical studies are crucial players in the journey to develop new and more efficacious treatment options for patients with rare diseases. On June 10, 2021, Vertex Pharmaceuticals Incorporated ("Vertex") shared…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More